YAVNE, Israel--(BUSINESS WIRE)--
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical
company bringing innovative therapies to address unmet needs in severe
burn and wound management, today announced that the Company will release
financial results for the three and nine months ended September 30,
2014, after the market close on Wednesday, November 5, 2014.
Following the release, MediWound's management will host a conference
call for the investment community beginning at 4:30 p.m. ET on
Wednesday, November 5, 2014, to discuss the financial results and to
answer questions.
Shareholders and other interested parties may participate in the
conference call by dialing (877) 602-7189 (domestic) or (678) 894-3057
(international) and entering passcode 26917687. The call also will be
broadcast live on the Internet at www.streetevents.com
and www.mediwound.com.
A replay of the call will be accessible two hours after its completion
through November 11, 2014 by dialing (855) 859-2056 (domestic) or (404)
537-3406 (international) and entering passcode 26917687. The call will
also be archived for 90 days at www.streetevents.com
and www.mediwound.com.
About MediWound Ltd.
MediWound is a fully integrated biopharmaceutical company focused on
developing, manufacturing and commercializing novel therapeutics based
on its patented proteolytic enzyme technology to address unmet needs in
the fields of severe burns, chronic and other hard-to-heal wounds.
MediWound's first innovative biopharmaceutical product, NexoBrid,
received marketing authorization from the European Medicines Agency for
removal of dead or damaged tissue, known as eschar, in adults with deep
partial and full-thickness thermal burns and was launched in Europe.
NexoBrid represents a new paradigm in burn care management, and clinical
trials have demonstrated, with statistical significance, its ability to
non-surgically and rapidly remove the eschar earlier and, without
harming viable tissues. For more information, please visit www.mediwound.com.
MediWound
Sharon Malka
CFO
ir@mediwound.co.il
or
LHA
Anne
Marie Fields, 212-838-3777
Senior Vice President
afields@lhai.com
Source: MediWound Ltd.
News Provided by Acquire Media